Gilead Sciences Inc (NASDAQ:GILD) closed its 2025 fiscal year with a fourth-quarter performance that surpassed Wall Street's expectations, though a cautious outlook for the coming year appears to be weighing on investor sentiment in after-hours trading.
Fourth-Quarter Results: A Clean Beat
The biopharmaceutical giant reported Q4 2025 revenue of $7.93 billion, a 5% increase over the same period last year and modestly ahead of the analyst consensus estimate of $7.85 billion. The company's non-GAAP earnings per share (EPS) of $1.86 also topped the estimated $1.85.
The quarterly strength was primarily driven by the company's core HIV franchise and newer liver disease products, which offset continued declines in sales of the COVID-19 treatment Veklury. Key product performances included:
- HIV Portfolio: Sales grew 6% year-over-year to $5.8 billion. Flagship drug Biktarvy saw sales rise 5% to $4.0 billion, while Descovy sales surged 33% to $819 million, fueled by demand for HIV prevention.
- Liver Disease: The portfolio grew 17% to $844 million, driven by the newer therapy Livdelzi.
- Oncology: Sales were essentially flat at $842 million. The breast cancer drug Trodelvy grew 8% to $384 million, but this was offset by a 6% decline in cell therapy products like Yescarta and Tecartus due to competitive pressures.
- Veklury: As anticipated, sales of the antiviral fell 37% to $212 million, reflecting lower COVID-19 hospitalization rates.
The Outlook: Guidance Falls Short of Expectations
While the fourth quarter delivered a beat, management's financial guidance for the full 2026 fiscal year came in below what analysts had been modeling. This divergence is the most likely catalyst for the stock's negative reaction in extended trading.
The company provided the following 2026 outlook:
- Product Sales: $29.6 billion to $30.0 billion (midpoint: $29.8 billion)
- Non-GAAP Diluted EPS: $8.45 to $8.85 (midpoint: $8.65)
This sales guidance midpoint is approximately 1.2% below the analyst consensus estimate of $30.2 billion. The EPS guidance midpoint is roughly 2.3% below the consensus estimate of $8.86. The company's forecast assumes Veklury sales will stabilize at around $600 million for the year.
Market Reaction and Analyst Sentiment
The immediate market reaction reflects the tension between a strong quarterly beat and a softer-than-expected forward view. Headlines following the report captured this dichotomy, noting the "solid fourth quarter" but highlighting the "light outlook" that "falls short of Wall Street's expectations."
This guidance suggests that while Gilead's core business remains robust, the market's growth expectations for 2026 may need to be tempered. Investors are likely weighing the steady performance of the HIV division and promising launches like Yeztugo and Livdelzi against the ongoing challenges in the competitive oncology segment and the diminished contribution from Veklury.
Strategic Highlights and Pipeline Updates
Beyond the financials, the earnings release highlighted several key developments:
- Positive Phase 3 results for a new investigational once-daily HIV regimen combining bictegravir and lenacapavir.
- A new label update for Yescarta, broadening its eligible patient population.
- The presentation of new long-term data reinforcing the safety and efficacy of Livdelzi for liver disease.
- The announcement of a 3.8% increase in the quarterly dividend to $0.82 per share, underscoring the company's commitment to shareholder returns.
Conclusion
Gilead Sciences delivered a conclusive beat for the final quarter of 2025, demonstrating the underlying strength of its virology business. However, the company's conservative guidance for 2026 has introduced uncertainty, leading to a negative after-market reaction as investors recalibrate near-term growth expectations. The coming year will be pivotal for Gilead as it seeks to build on recent launches and advance its pipeline while navigating a post-Veklury revenue landscape.
For a detailed breakdown of future earnings estimates and historical performance, review the Gilead Sciences earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.